116 related articles for article (PubMed ID: 27048234)
1. GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity.
Amato A; Baldassano S; Mulè F
J Endocrinol; 2016 May; 229(2):R57-66. PubMed ID: 27048234
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet.
Baldassano S; Amato A; Cappello F; Rappa F; Mulè F
J Endocrinol; 2013 Apr; 217(1):11-20. PubMed ID: 23308022
[TBL] [Abstract][Full Text] [Related]
3. Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2.
Baldassano S; Bellanca AL; Serio R; Mulè F
J Endocrinol; 2012 Jun; 213(3):277-84. PubMed ID: 22457516
[TBL] [Abstract][Full Text] [Related]
4. GLP-2 as Beneficial Factor in the Glucose Homeostasis in Mice Fed a High Fat Diet.
Baldassano S; Rappa F; Amato A; Cappello F; Mulè F
J Cell Physiol; 2015 Dec; 230(12):3029-36. PubMed ID: 25967277
[TBL] [Abstract][Full Text] [Related]
5. Adropin and glucagon-like peptide-2 are associated with glucose metabolism in obese children.
Chen RM; Yuan X; Ouyang Q; Lin XQ; Ai ZZ; Zhang Y; Yang XH
World J Pediatr; 2019 Dec; 15(6):565-571. PubMed ID: 31598832
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
[TBL] [Abstract][Full Text] [Related]
7. WR-GLP2, a glucagon-like peptide 2 from hybrid crucian carp that protects intestinal mucosal barrier and inhibits bacterial infection.
Tang Y; Feng M; Zhu X; Long J; Zhou Z; Liu S
Fish Shellfish Immunol; 2022 Mar; 122():29-37. PubMed ID: 35085736
[TBL] [Abstract][Full Text] [Related]
8. Postprandial glucagon-like peptide-1 secretion is increased during the progression of glucose intolerance and obesity in high-fat/high-sucrose diet-fed rats.
Nakajima S; Hira T; Hara H
Br J Nutr; 2015 May; 113(9):1477-88. PubMed ID: 25827219
[TBL] [Abstract][Full Text] [Related]
9. Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats.
Shan CY; Yang JH; Kong Y; Wang XY; Zheng MY; Xu YG; Wang Y; Ren HZ; Chang BC; Chen LM
J Endocrinol; 2013 Sep; 218(3):255-62. PubMed ID: 23757509
[TBL] [Abstract][Full Text] [Related]
10. Hypothalamic Insulin Resistance in Obesity: Effects on Glucose Homeostasis.
Chen W; Balland E; Cowley MA
Neuroendocrinology; 2017; 104(4):364-381. PubMed ID: 28122381
[TBL] [Abstract][Full Text] [Related]
11. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
[TBL] [Abstract][Full Text] [Related]
12. Genetic ablation of lymphocytes and cytokine signaling in nonobese diabetic mice prevents diet-induced obesity and insulin resistance.
Friedline RH; Ko HJ; Jung DY; Lee Y; Bortell R; Dagdeviren S; Patel PR; Hu X; Inashima K; Kearns C; Tsitsilianos N; Shafiq U; Shultz LD; Lee KW; Greiner DL; Kim JK
FASEB J; 2016 Mar; 30(3):1328-38. PubMed ID: 26644351
[TBL] [Abstract][Full Text] [Related]
13. Diabetes, obesity, and the brain.
Schwartz MW; Porte D
Science; 2005 Jan; 307(5708):375-9. PubMed ID: 15662002
[TBL] [Abstract][Full Text] [Related]
14. Mice Deficient in Proglucagon-Derived Peptides Exhibit Glucose Intolerance on a High-Fat Diet but Are Resistant to Obesity.
Takagi Y; Kinoshita K; Ozaki N; Seino Y; Murata Y; Oshida Y; Hayashi Y
PLoS One; 2015; 10(9):e0138322. PubMed ID: 26378455
[TBL] [Abstract][Full Text] [Related]
15. Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance.
Wang XA; Zhang R; Zhang S; Deng S; Jiang D; Zhong J; Yang L; Wang T; Hong S; Guo S; She ZG; Zhang XD; Li H
Am J Physiol Endocrinol Metab; 2013 Aug; 305(4):E485-95. PubMed ID: 23695216
[TBL] [Abstract][Full Text] [Related]
16. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure.
Knauf C; Cani PD; Ait-Belgnaoui A; Benani A; Dray C; Cabou C; Colom A; Uldry M; Rastrelli S; Sabatier E; Godet N; Waget A; Pénicaud L; Valet P; Burcelin R
Endocrinology; 2008 Oct; 149(10):4768-77. PubMed ID: 18556349
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 2 in colon carcinogenesis: possible target for anti-cancer therapy?
Kannen V; Garcia SB; Stopper H; Waaga-Gasser AM
Pharmacol Ther; 2013 Jul; 139(1):87-94. PubMed ID: 23583681
[TBL] [Abstract][Full Text] [Related]
18. Transient receptor potential vanilloid type-1 channel regulates diet-induced obesity, insulin resistance, and leptin resistance.
Lee E; Jung DY; Kim JH; Patel PR; Hu X; Lee Y; Azuma Y; Wang HF; Tsitsilianos N; Shafiq U; Kwon JY; Lee HJ; Lee KW; Kim JK
FASEB J; 2015 Aug; 29(8):3182-92. PubMed ID: 25888600
[TBL] [Abstract][Full Text] [Related]
19. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
Tomas E; Wood JA; Stanojevic V; Habener JF
Regul Pept; 2011 Aug; 169(1-3):43-8. PubMed ID: 21549160
[TBL] [Abstract][Full Text] [Related]
20. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
Otto Buczkowska E; Dworzecki T
Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
